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required?To the Editor:
We read with interest the position statement based on the EASL
special conference 2013 dealing with ‘‘Bacterial infections in
cirrhosis’’ [1].
Infections in cirrhotic patients are a major problem, both in
terms of the high frequency and also the relative high risk of
associated mortality. Whilst there has already been signiﬁcant
progress, greater knowledge of the pathophysiology and
improvements in the management of these patients are still
crucial. Among the parameters associated with a risk of infection,
those that can be readily addressed during management are of
particular interest. Among them gastrointestinal bleeding, the
severity of the liver insufﬁciency, low protein ascites and a previ-
ous episode of infection are clinical situations that may justify a
primary or a secondary prophylaxis [1]. Randomized control
trials, testing some of these strategies, are in progress (for
example, the interest of norﬂoxacin in the primary prophylaxis
against SBP in patients with ascites, NCT01037959).
We also wish to highlight another recently described risk
factor that should be sought by hepatologists, vitamin D
deﬁciency (<10 ng/ml). We have recently published data thatdemonstrate an association between severe deﬁciency in
vitamin D and occurrence of bacterial infection in cirrhotic
patients, independent of the severity of the liver insufﬁciency,
assessed by the Child-Pugh or MELD score [2]. Whilst causality
could not be tested in our prospective observational study,
many other studies have also suggested that vitamin D could
be implicated in the interactions between the host and bacteria.
The anti-bacterial effects of vitamin D may be mediated, but
not only through an increase in the innate immune system
defence [3]. The potential link between infections and vitamin
D deﬁciency has also been recently suggested in patients in
resuscitation units [4].
Vitamin D deﬁciency is frequent in the general population
and has been associated with increased mortality [5]. Prospec-
tive trials of supplementation of vitamin D with calcium in
the elderly reduced osteoporotic fractures and mortality [6].
Cirrhotic patients also frequently exhibit a deﬁciency in vitamin
D and are exposed to osteoporosis [7]. In order to increase
bone health in patients with advanced liver disease, experts
(including the European Association for the Study of the Liver
guidelines for the management of patients suffering fromvol. 61 j 962–966 965
cholestatic liver diseases) suggest a balanced diet and a
supplementation with calcium (1000–1500 mg/day) and vitamin
D (400–800 IU/day), but little clinical data are available to
support this [7,8].
Moreover, alcoholic cirrhotic patients with a severe deﬁciency
in vitamin D (<10 ng/ml) have been suggested to have a higher
risk of death [9]. Vitamin D supplementation in cirrhotic patients
could be particularly beneﬁcial in term of morbidity, quality of
life and mortality.
In conclusion, we suggest that the potential association
between vitamin D deﬁciency and infection in cirrhotic patients
should be tested in independent large cohorts to conﬁrm these
preliminary data. If validated, a new strategy of supplementation
of vitamin D in cirrhotic patients (particularly those with 25-OH
vitamin D <10 ng/ml), both to reduce fracture risk and to reduce
intercurrent infections, should be tested in randomized control
trials.
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